クロストリディオイドス・ディフィシルの再発性感染症に対する糞便の微生物群による治療
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。糞便の微生物のサスペンションであるRebyotaは,腸内微生物を回復することによって,再発するClostridioides difficile感染症を予防します. 毒素の産生を抑制する有益な微生物を導入することで 効果があるようです
科学分野
- 微生物学
- 胃腸内科
- 感染症
背景
- 再発性Clostridioides difficile感染 (CDI) は臨床的に重大な課題となっている.
- 糞便微生物移植 (FMT) は,CDIの再発を予防するのに有効です.
- レビオタは,CDIの予防のために,標準化された,直腸内投与の糞微生物のサスペンションを提供しています.
研究 の 目的
- 再発性CDIを防ぐための新種の糞便微生物のサスペンションであるRebyotaを記述します.
- CDIの再発を防ぐためのRebyotaの作用メカニズムを明らかにする.
主な方法
- レビオタは,糞便の微生物群のサスペンションとして直腸に投与されます.
- この研究は,臨床試験のデータではなく,提案された作用機構に焦点を当てています.
主要な成果
- Rebyotaのメカニズムは,ドナー微生物によるC. difficileの競争的排除を伴う可能性が高い.
- 保護性腸内細菌群の回復と 微生物群の調節が 可能な要因である.
- 微生物の代謝産物とファグの活動も,Rebyotaの有効性に関与する可能性があります.
結論
- レビオタは,再発性CDIを予防するための潜在的な治療法です.
- そのメカニズムには 多面的な腸内微生物の回復と調節が含まれます
- さらなる研究により,様々な微生物と代謝成分の正確な貢献が明らかになるかもしれません.
関連する概念動画
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...